Redhill Biopharma Ltd.’s stock (NASDAQ:RDHL) has soared in recent days following news that the U.S. FDA granted five years of market exclusivity for Talicia, a first-line therapy for eradication of Helicobacter pylori infection, which affects about 35% of the U.S. adult population.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections.
After Cormedix Inc. navigated manufacturing issues that slowed the process, the U.S. FDA approved the antibacterial and antifungal solution Defencath to reduce catheter-related bloodstream infections adults with kidney failure.
The BioWorld Infectious Disease Index (BIDI) jumped 13.04% at the end of January and has been mostly on a downturn since, echoing trends that BioWorld analysis noted last year. BIDI ended October down 47.98%, lower than the Nasdaq Biotechnology Index and the Dow Jones Industrial Average, which were down 12.31% and 0.28%, respectively.
With Valneva SE’s accelerated approval from the U.S. FDA for chikungunya vaccine Ixchiq, attention turned to the February 2024 meeting of the Advisory Committee on Immunization Practices (ACIP), which will vote on the product. A single-dose, live-attenuated vaccine, Ixchiq is designed to prevent disease caused by the virus in people 18 and older who are at increased risk of exposure to the bug.
South Korea may soon gain its first domestically developed anthrax vaccine by GC Biopharma Corp., with the Korean biotech having filed Nov. 1 with the MFDS for approval of its novel recombinant protein anthrax vaccine called GC-1109.
At the 30th Annual Congress of the European Society for Gene and Cell Therapy in Brussels this week, researchers presented both preclinical and clinical strategies for applying gene therapy to a functional HIV cure. At a Wednesday session on Infectious Diseases & Vaccines, Alessio Nahmad, of Tabby Therapeutics Ltd., described using B cells edited to express broadly neutralizing antibodies (bnAbs) 3BNC117 to deliver high titers of antibodies in mice.
The World Health Organization recently endorsed an economical malaria vaccine with a 75% effectiveness rate, which costs less than half of the initial vaccine (RTS,S/AS01) created two years ago. The new vaccine, R21/Matrix-M, developed by the University of Oxford and the Serum Institute of India, marks a significant milestone after decades of scientific research.
What CEO Jason Okazaki called Assembly Biosciences Inc.’s “monumental” deal for new antivirals with Gilead Sciences Inc. brings $100 million right away, consisting of an $84.8 million up-front payment and a $15.2 million equity investment. Wall Street liked it, and shares of South San Francisco-based Assembly (NASDAQ:ASMB) closed Oct. 17 at $1.25, up 52 cents or 72%, on word of the 12-year arrangement. Gilead (NASDAQ:GILD) ended at $80.48, up $1.28.
In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.